سعر انسونيل اتش ان بي اتس 100 وحدة دولية/مل فيال 2022

Insunil H NPH: intermediate-acting isophane (NPH) human insulin, 100 IU/ml, one vial (Sedico; listed in Egypt as Sedico > El Nile). Vial volume not stated by the sources opened.

• To improve glycemic control in adults and pediatric patients with diabetes mellitus.Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)

• Hypoglycaemia, hypersensitivity reactions and hypokalaemia; post-approval reports include localized cutaneous amyloidosis at the injection site.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity reactions to the insulin or any of its excipients.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Contraindicated during episodes of hypoglycaemia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Never share pens, cartridges, needles or syringes between patients, even if the needle is changed (risk of blood-borne infection).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• All insulins shift potassium into cells and may cause hypokalaemia, which if untreated can cause respiratory paralysis, ventricular arrhythmia and death; severe life-threatening generalized allergy including anaphylaxis can occur.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Thiazolidinediones (PPAR-gamma agonists, e.g. pioglitazone)Dose-related fluid retention that may lead to or worsen heart failure; observe for heart failure and consider dose reduction or discontinuation of the thiazolidinedione.DailyMed (U.S. National Library of Medicine)
• Oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, salicylates, sulphonamide antibioticsMay enhance the glucose-lowering effect and increase susceptibility to hypoglycaemia.European Medicines Agency (EMA) - EPAR product information
• Corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens/progestogens, phenothiazines, somatropin, sympathomimetics, thyroid hormones, protease inhibitors, atypical antipsychoticsMay reduce the glucose-lowering effect.European Medicines Agency (EMA) - EPAR product information

• Published data over decades have not established an association between human insulin use in pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes; poorly controlled diabetes carries maternal and fetal risks.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Exogenous human insulin is transferred into human milk; no adverse reactions in breastfed infants have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Insulin isophane human (NPH): Lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat and by inhibiting hepatic glucose production; as an isophane suspension it has a gradual onset and long duration of action compared with soluble insulin.